Orfiril Long (Sodium Valproate)

Sodium valproate, the active ingredient in Orfiril Long, is an anticonvulsant presented as a oral formulation for systemic use. It treats epilepsy, bipolar disorder, and migraine prophylaxis in adults and children as prescribed by a healthcare professional.

GNH USA supplies Orfiril Long as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orfiril Long is an antiepileptic drug that acts on neuronal excitability in several neurological and psychiatric conditions. - Epilepsy: Reduces the frequency and severity of seizures. - Bipolar disorder: Stabilises mood and prevents manic episodes. - Migraine prophylaxis: Decreases the number of migraine attacks per month.

Adverse reactions to sodium valproate may vary in frequency and severity.

Common Side Effects: - Nausea and vomiting - Tremor - Weight gain - Hair loss - Drowsiness - Elevated liver enzymes

Serious or Rare Side Effects: - Severe liver injury - Pancreatitis - Thrombocytopenia - Hyperammonemia - Stevens‑Johnson syndrome - Acute encephalopathy

When prescribing Orfiril Long, clinicians should consider several safety aspects. - Monitor liver function: Regular blood tests for hepatic enzymes. - Assess platelet count: Periodic complete blood count to detect thrombocytosis. - Evaluate renal ? ? "); - Pregnancy: Use only "); - Contra‑  - Store at below 25°C: keep "); -  t

The pharmacological profile of  ");\n "  " ");